Arrowgrass Capital Partners’s AbbVie ABBV Stock Holding History

Arrowgrass Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-20,000	Closed	-$1.09M	–	23
2015 Q3	$1.09M	Buy	+20,000	New	+$1.3M	0.58%	16
2015 Q2	–	Sell	-442,000	Closed	-$25.9M	–	17
2015 Q1	$25.9M	Buy	+442,000	New	+$26.7M	4.31%	5

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Arrowgrass Capital Partners's ABBV Position: Q4 2015 in Review

Arrowgrass Capital Partners sold out of AbbVie (ABBV) in Q4 2015, closing a stake of 20,000 shares — an estimated $1.09M sold.

Arrowgrass Capital Partners first reported a position in ABBV in Q1 2015 and held it in 2 quarters. The position peaked at $25.9M in Q1 2015. 1,637 funds tracked by Wall St. Rank hold ABBV as of Q4 2015.

Arrowgrass Capital Partners reported no remaining AbbVie position as of Q4 2015 after selling out during the quarter.
Arrowgrass Capital Partners sold 20,000 AbbVie shares in Q4 2015, an estimated $1.09M.
Arrowgrass Capital Partners first reported a position in AbbVie in Q1 2015 and held it in 2 quarters.
Arrowgrass Capital Partners's AbbVie position peaked at $25.9M in Q1 2015.
1,637 funds tracked by Wall St. Rank held AbbVie as of Q4 2015.

Based on Arrowgrass Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.